BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32817299)

  • 1. Can population
    Qin Z; Kuok CN; Dong H; Jiang L; Zhang L; Guo M; Leong HK; Wang L; Meng G; Wang SM
    J Med Genet; 2021 Sep; 58(9):587-591. PubMed ID: 32817299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
    Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
    Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
    Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
    Manchanda R; Burnell M; Gaba F; Desai R; Wardle J; Gessler S; Side L; Sanderson S; Loggenberg K; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Legood R; Beller U; Tomlinson I; Menon U; Jacobs I
    BJOG; 2020 Feb; 127(3):364-375. PubMed ID: 31507061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary breast cancer in Jews.
    Rubinstein WS
    Fam Cancer; 2004; 3(3-4):249-57. PubMed ID: 15516849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current detection rates and time-to-detection of all identifiable
    Manchanda R; Blyuss O; Gaba F; Gordeev VS; Jacobs C; Burnell M; Gan C; Taylor R; Turnbull C; Legood R; Zaikin A; Antoniou AC; Menon U; Jacobs I
    J Med Genet; 2018 Aug; 55(8):538-545. PubMed ID: 29622727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing.
    Metcalfe KA; Poll A; Royer R; Nanda S; Llacuachaqui M; Sun P; Narod SA
    Br J Cancer; 2013 Aug; 109(3):777-9. PubMed ID: 23778531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
    Lacour RA; Westin SN; Meyer LA; Wingo SN; Schorge JO; Brooks R; Mutch D; Molina A; Sutphen R; Barnes M; Elder J; Teoh D; Powell CB; Choubey V; Blank S; Macdonald HR; Brady MF; Urbauer DL; Bodurka D; Gershenson DM; Lu KH
    Gynecol Oncol; 2011 May; 121(2):358-63. PubMed ID: 21276604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
    Kirchhoff T; Satagopan JM; Kauff ND; Huang H; Kolachana P; Palmer C; Rapaport H; Nafa K; Ellis NA; Offit K
    J Natl Cancer Inst; 2004 Jan; 96(1):68-70. PubMed ID: 14709740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
    Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.
    Metcalfe KA; Poll A; Royer R; Llacuachaqui M; Tulman A; Sun P; Narod SA
    J Clin Oncol; 2010 Jan; 28(3):387-91. PubMed ID: 20008623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.